title: Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al.
authors.forename: C J
authors.initials: CJ
authors.lastname: van der Laken
authors.forename: W F
authors.initials: WF
authors.lastname: Lems
authors.forename: R M
authors.initials: RM
authors.lastname: van Soesbergen
authors.forename: J J
authors.initials: JJ
authors.lastname: van der Sande
authors.forename: B A C
authors.initials: BA
authors.lastname: Dijkmans
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D010264:Paraplegia / Q000139:chemically induced* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept